In the latest development in the court battle between Eli Lilly And Co (NYSE: LLY) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) over an Alimta patent, the U.S. Court of Appeals ruled that Teva was liable for inducing patent infringement by physicians.
This decision supported that of a lower court, which issued a ruling in August 2015 granting Teva five years of exclusive ownership of the cancer drug.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
"We are disappointed with the Court's decision," a Teva spokesperson told Benzinga.
For Eli Lilly, the victory was a positive turning point in its battle against patent infringements. The company previously lost its fight for exclusive rights to Alimta in the European Union.
Eli Lilly shares were up 2 percent at $76.96, while Teva shares were down 0.23 percent on Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.